<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
BCR–ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response

pmid: 22233112
BCR–ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response
In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.
- Masaryk University Czech Republic
- Central European Institute of Technology Czech Republic
Gene Expression Regulation, Leukemic, Fusion Proteins, bcr-abl, Nuclear Proteins, Antigens, CD34, Antineoplastic Agents, Flow Cytometry, Models, Biological, Piperazines, Inhibitory Concentration 50, Pyrimidines, Treatment Outcome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Benzamides, Imatinib Mesylate, Humans, Adaptor Proteins, Signal Transducing, Signal Transduction
Gene Expression Regulation, Leukemic, Fusion Proteins, bcr-abl, Nuclear Proteins, Antigens, CD34, Antineoplastic Agents, Flow Cytometry, Models, Biological, Piperazines, Inhibitory Concentration 50, Pyrimidines, Treatment Outcome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Benzamides, Imatinib Mesylate, Humans, Adaptor Proteins, Signal Transducing, Signal Transduction
69 Research products, page 1 of 7
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
chevron_left - 1
- 2
- 3
- 4
- 5
chevron_right
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).4 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average